

## DAFTAR PUSTAKA

1. Penazzato M, Irvine C, Vicari M, Essajee SM, Sharma A, Puthanakit T, *et al.* A global research agenda for pediatric HIV. *J Acquir Immune Defic Syndr.* 2018;78:S10–5.
2. Ningsih IK, Hastuti S. Kajian pencegahan penularan HIV dari ibu ke anak pada antenatal care oleh bidan praktik mandiri di Yogyakarta. *J Adm Kesehat Indones.* 2018;6:61.
3. Fry S, Barnabas SL, Cotton MF. Tuberculosis and HIV - an update on the “cursed duet” in children. *Front Pediatr.* 2019;7:1–11.
4. Sugihantono A. Laporan perkembangan HIV-AIDS & infeksi menular seksual triwulan IV tahun 2017. Kementerian Kesehatan Republik Indonesia. 2018. p. 1–565.
5. Mirrakhimov AE, Ali AM, Barbaryan A, Prueksaritanond S. Human immunodeficiency virus and pulmonary arterial hypertension. *ISRN Cardiol.* 2013;2013:1–11.
6. Mehta N, Khan I, Mehta R, Sepkowitz D. HIV-related pulmonary hypertension : analytic review of 131 cases. *Chest.* 2000;118:1133–41.
7. Putri AJ, Darwin E, Efrida. Pola infeksi oportunistik yang menyebabkan kematian pada penyandang AIDS di RS Dr . M . Djamil Padang Tahun 2010- 2012. *J Kesehat Andalas.* 2015;4:10–6.
8. Sulastini, Kurniawan A, Syamsu, Matulessy P, Christianto E, Prawitasari T. Pedoman pelayanan gizi bagi ODHA. Kementerian Kesehatan Republik Indonesia. 2010. p. 1–38.
9. UNICEF. Addressing the global HIV epidemic among pregnant women, mothers, children and adolescents. 2018. p. 1–19.
10. Isni K. Dukungan keluarga, dukungan petugas kesehatan, dan perilaku ibu HIV dalam pencegahan penularan HIV/AIDS ke bayi. *J Kesehat Masy.* 2016;11:1–9.
11. Rahmawati M. Penanggulangan HIV/AIDS di Indonesia dalam ancaman RKUHP. 2019. p. 1–98.

12. Seitz R. Human immunodeficiency virus (HIV). *Transfus Med Hemotherapy*. 2016;43:203–22.
13. National AIDS Control Organization. National guidelines for HIV testing. New Delhi: Ministry of Health & Family Welfare Government of India; 2015. p. 1–120.
14. Ngwende S, Gombe NT, Midzi S, Tshimanga M, Shambira G, Chadambuka A. Factors associated with HIV infection among children born to mothers on the prevention of mother to child transmission programme at Chitungwiza Hospital, Zimbabwe, 2008. *BMC Public Health*. 2013;13:1–8.
15. Wang Q, Wang L, Fang L, Wang A, Jin X, Wang F, *et al*. Timely antiretroviral prophylaxis during pregnancy effectively reduces HIV mother-to-child transmission in eight counties in China: A prospective study during 2004-2011. *Sci Rep*. 2016;6:1–8.
16. World Health Organization. Prevention of HIV in infants and young children : review of evidence and WHO's activities. Switzerland; 2002. p. 1–6.
17. Menteri Kesehatan Republik Indonesia. Pedoman nasional pelayanan kedokteran: tatalaksana HIV. 2019. p. 1–220.
18. Sütçü M, Acar M, Aktürk H, Hançerli Torun S, Beka H, Ağaçfidan A, *et al*. Clinical findings of pediatric HIV infection in a tertiary center in Turkey. *Balkan Med J*. 2017;34:239–45.
19. Kementerian Kesehatan Republik Indonesia. Pedoman penerapan terapi HIV pada anak. In: Kurniati N, editor. 2014. p. 1–96.
20. Rahmadini Y, Andrajati R, Andalusia R. Perbandingan efikasi beberapa kombinasi antiretroviral pada pasien HIV/AIDS ditinjau dari kenaikan jumlah CD4 rata-rata di RSK Dharmais Jakarta. *Maj Ilmu Kefarmasian*. 2008;5:67–74.
21. Mutwa PR, Boer KR, Asimwe-Kateera B, Tuyishimire D, Muganga N, Lange JMA, *et al*. Safety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected Rwandan children: A prospective study. *PLoS One*. 2014;9:1–12.

22. Chawla KS, Rosenberg NE, Stanley C, Matoga M, Maluwa A, Kanyama C, *et al.* HIV and early hospital readmission : evaluation of a tertiary medical facility in Lilongwe , Malawi. *BMC Health Serv Res.* 2018;18:1–9.
23. Ford N, Vitoria M, Penazzato M, Doherty M, Shubber Z, Meintjes G, *et al.* Causes of hospital admission among people living with HIV worldwide: A systematic review and meta-analysis. *Lancet HIV.* 2015;2:1–7.
24. Karyadi T. Keberhasilan pengobatan antiretroviral (ARV). *J Penyakit Dalam Indones.* 2017;4:2–4.
25. Pham H V., Ishizaki A, Nguyen L V., Phan CTT, Phung TTB, Takemoto K, *et al.* Two-year outcome of first-line antiretroviral therapy among HIV-1 vertically-infected children in Hanoi, Vietnam. *Int J STD AIDS.* 2015;26:821–30.
26. Duong T, Judd A, Collins IJ, Doerholt K, Lyall H, Foster C, *et al.* Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland. *Aids.* 2014;28:2395–405.
27. Anggriani Y, Rianti A, Pontoan J, Juwita Y. Analisis efektivitas terapi antiretroviral pada pasien HIV/AIDS rawat jalan di RSUP Fatmawati Jakarta tahun 2016. *J Ilm Ibnu Sina.* 2019;4:9–18.
28. Ben-Farhat J, Schramm B, Nicolay N, Wanjala S, Szumilin E, Balkan S, *et al.* Mortality and clinical outcomes in children treated with antiretroviral therapy in four African vertical programmes during the first decade of paediatric HIV care, 2001–2010. *Trop Med Int Heal.* 2017;22:340–50.
29. Arage G, Assefa M, Worku T, Semahegn A. Survival rate of HIV-infected children after initiation of the antiretroviral therapy and its predictors in Ethiopia: A facility-based retrospective cohort. *SAGE Open Med.* 2019;7:1–8.
30. Pozniak A. Quality of life in chronic HIV infection. *Lancet HIV.* 2014;1:e6–7.
31. Anna Thereza Thome Leao AKB. Evaluation of quality of life in HIV-infected children and children with cancer. *Dentistry.* 2015;5:1–7.
32. Mchenry MS, Nyandiko WM, Scanlon ML, Fischer LJ, Mcateer CI, Aluoch

- J, *et al.* HIV Stigma: Perspectives from Kenyan child caregivers and adolescents living with HIV. *J Int Assoc Provid AIDS Care*. 2017;16:215–25.
33. Barennes H, Tat S, Reinharz D, Vibol U. Perceived stigma by children on antiretroviral treatment in Cambodia. *BMC Pediatr*. 2014;14:1–9.
  34. Sumantri R, Supandiman I, Indjradinata P, van der Ven A, van Crevel R. Peluang kematian penderita Human Immunodeficiency Virus-Acquired Immune Deficiency Syndrome berdasarkan gabungan derajat anemia, indeks massa tubuh, dan jumlah cluster differentiation 4. *Maj Kedokt Bandung*. 2012;44:50–6.
  35. Kabue MM, Buck WC, Wanless SR, Cox CM, McCollum ED, Caviness AC, *et al.* Mortality and clinical outcomes in HIV-infected children on antiretroviral therapy in Malawi, Lesotho, and Swaziland. *Pediatrics*. 2012;130:e591–9.
  36. Perwitasari D, Arguni E, Satria CD, Hapsari M. Faktor prediktor kematian anak dengan infeksi HIV yang mendapat terapi antiretrovirus di RSUP Dr. Sardjito Yogyakarta dan RSUP Dr. Kariadi Semarang. *Sari Pediatr*. 2017;18:1–6.
  37. L’Huillier AG, Posfay-Barbe KM, Pictet H, Beghetti M. Pulmonary Arterial Hypertension among HIV-Infected Children: Results of a National Survey and Review of the Literature. *Front Pediatr*. 2015;3:1–10.
  38. Melkamu MW, Gebeyehu MT, Afenigus AD, Hibstie YT, Temesgen B, Petrucka P, *et al.* Incidence of common opportunistic infections among HIV-infected children on ART at Debre Markos referral hospital, Northwest Ethiopia: a retrospective cohort study. *BMC Infect Dis*. 2020;20:1–12.
  39. Nesheim SR, Kapogiannis BG, Soe MM, Sullivan KM, Abrams E, Farley J, *et al.* Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the perinatal AIDS collaborative transmission study, 1986-2004. *Pediatrics*. 2007;120:100–9.
  40. Low A, Gavrilidis G, Larke N, B-Lajoie MR, Drouin O, Stover J, *et al.*

- Incidence of opportunistic infections and the impact of antiretroviral therapy among HIV-infected adults in low- and middle-income countries: A systematic review and meta-analysis. *Clin Infect Dis*. 2016;62:1595–603.
41. Kementerian Kesehatan Republik Indonesia. TB Indonesia: TB/HIV. 2016.
  42. Marais BJ, Rabie H, Schaaf SH, Cotton MF. Common opportunistic infections in HIV infected infants and children Part 1 - Respiratory infections. *South African Fam Pract*. 2006;48:52–6.
  43. Gie R. Management of TB in the HIV-infected child. *Int J Tuberc Lung Dis*. 2006;10:1331–6.
  44. Moussa HS, Bayoumi FS, Mohamed AMA. Gene Xpert for direct detection of Mycobacterium Tuberculosis in stool specimens from children with presumptive pulmonary tuberculosis. *Ann Clin Lab Sci*. 2016;46:198–203.
  45. Grimwade K, Swingle GH. Cotrimoxazole prophylaxis for opportunistic infections in children with HIV infection. *Cochrane Database Syst Rev*. 2006;1:1–8.
  46. U.S. Department of Health and Human Services. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. AIDSinfo. 2019. p. 1–19.
  47. Departemen Kesehatan Republik Indonesia. Pedoman Nasional tatalaksana Klinis Infeksi HIV dan terapi antiretroviral pada orang dewasa. Jakarta; 2011. 1-108 p.
  48. World Health Organization. WHO recommendations on the management of diarrhoea and pneumonia in HIV-infected infants. World Health Organization. Geneva; 2010. 1-60 p.
  49. Limper AH, Adenis A, Le T, Harrison TS. Fungal infections in HIV/AIDS. *Lancet Infect Dis*. 2017;17:1–10.
  50. World Health Organization. Management of opportunistic infections and general symptoms of HIV/AIDS: Clinical protocol for the WHO European region. 2012. 1-35 p.
  51. Rose AM, Hall CS, Martinez-Alier N. Aetiology and management of malnutrition in HIV-positive children. *Arch Dis Child*. 2014;99:546–51.

52. World Health Organization. Guidelines for an integrated approach to the nutritional care of HIV-infected children (6 months-14 years). 2009. 1-92 p.
53. Arpadi S. Growth failure in HIV-infected children. World Health Organization. 2005. 1-25 p.
54. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. 2010. 1-206 p.
55. Nuttall JJC, Eley BS. BCG vaccination in HIV-infected children. *Tuberc Res Treat.* 2011;2011:1-6.
56. Rezeki S. Pedoman imunisasi di Indonesia satgas imunisasi. 6th editio. Ranuh I, Hadinegoro S, Kartasasmita C, Ismoedijanto, Soedjatmiko, Gunardi H, editors. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia; 2011. 456 p.
57. Siberry GK, Abzug MJ, Nachman S, Brady MT, Dominguez KL, Handelsman E, *et al.* Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. 2019. 1-409 p.
58. Mehta K, Heylen E, Shet A. Adherence to antiretroviral therapy among children living with HIV in South India. *AIDS Behav.* 2016;20:1076-83.
59. Mbuagbaw L, Mertz D, Lawson DO, Smieja M, Benoit AC, Alvarez E, *et al.* Strategies to improve adherence to antiretroviral therapy and retention in care for people living with HIV in high- income countries : a protocol for an overview of systematic reviews. *BMJ Open.* 2018;8:1-5.
60. Tola HH, Tol A, Shojaeizadeh D. Tuberculosis treatment non-adherence and lost to follow up among TB patients with or without HIV in developing countries : A systematic review. *Iran J Public Heal.* 2015;44:1-11.
61. Ministry of Health and Social Welfare. National guidelines for the management of HIV and AIDS. Fifth edit. Tanzania: National AIDS Control Programme (NCAP); 2015. 1-290 p.
62. Bristol Myers Squibb Virology. Zerit (stavudine). Unites States: A Bristol-Myers Squibb Company; 2002. 1-27 p.
63. Anderson PL, Rower JE. Zidovudine and lamivudine for HIV infection.

*Clin Med Rev Ther.* 2010;2:1–19.

64. Dheda M. Efavirenz and neuropsychiatric effects. *South Afr J HIV Med.* 2017;18:1.
65. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan. Petunjuk teknis manajemen dan tatalaksana TB pada anak. Jakarta: Kementerian Kesehatan Republik Indonesia; 2016. 1-90 p.
66. Bigna JJR, Sime PSD, Koulla-Shiro S. HIV related pulmonary arterial hypertension: Epidemiology in Africa, physiopathology, and role of antiretroviral treatment. *AIDS Res Ther.* 2015;12:1–8.
67. Tcherakian C, Rivaud E, Zucman D, Metivier AC, Couderc LJ. Curing HIV-associated pulmonary arterial hypertension. *Eur Respir J.* 2012;39:1045–6.
68. Ren L, Li J, Zhou S, Xia X, Xie Z, Liu P, et al. Prognosis of HIV patients receiving antiretroviral therapy according to CD4 counts : A long-term follow-up study in Yunnan , China. *Sci Rep.* 2017;1–7.
69. Cardoso C, Pinto JA, Candiani TMS, Carvalho I, Dantas A, Goulart E. Assessment of the prognostic value of the World Health Organization clinical staging system for HIV/AIDS in HIV-infected children and adolescents in a cohort in Belo Horizonte, Brazil. *J Trop Pediatr.* 2012;58:353–9.
70. Meidani M, Rezaei F, Maracy MR, Avijgan M. Prevalence, severity, and related factors of anemia in HIV/AIDS patients. *J Res Med Sci.* 2012;49:1–6.
71. Cunha G, Santis D, Menezes D, Crivelenti F, Branda RA, Zomer R, et al. International journal of infectious diseases hematological abnormalities in HIV-infected patients. *Int J Infect Dis.* 2011;15:e808–11.
72. Muhaimin T. Kualitas hidup anak remaja pada keluarga dengan HIV/AIDS di Indonesia. *J Kesehat Masy Nas.* 2010;5:131–8.
73. Soetjiningih. Tumbuh kembang anak. Jakarta: EGC; 1995.
74. Satgas Imunisasi Ikatan Dokter Anak Indonesia. Pedoman imunisasi di Indonesia. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia; 2011.

75. Barnett CF, Machado RF. Sildenafil in the treatment of pulmonary hypertension. *Vasc Health Risk Manag.* 2006;2:411–22.
76. Kementerian Kesehatan Republik Indonesia. Persyaratan kesehatan perumahan. Jakarta: Keputusan Menteri Kesehatan RI; 1999. p. 1–6.
77. Abbassi V. Growth and normal puberty. *Pediatrics.* 1998;102:507–11.
78. Varni JW, Planning U. Scaling and scoring of the pediatric quality of life inventory PedsQL. 2017. 1-146 p.
79. Katona P, Katona-apte J. The interaction between nutrition and infection. *Clin Infect Dis.* 2008;46:1582–8.
80. Tekleab AM, Tadesse BT, Giref AZ, Shimelis D, Gebre M. Anthropometric improvement among HIV infected pre-school children following initiation of first line anti-retroviral therapy : implications for follow up. *PLoS One.* 2016;11:1–14.
81. Hughes SM, Amadi B, Mwiya M, Nkamba H, Mulundu G, Tomkins A, *et al.* CD4 counts decline despite nutritional recovery in HIV-infected Zambian children with severe malnutrition. *Pediatrics.* 2009;123:e347–51.
82. Golucci APBS, Marson FAL, Valente MFF, Branco MM, Prado CC, Nogueira RJN. Influence of AIDS antiretroviral therapy on the growth pattern. *J Pediatr (Rio J).* 2018;652:1–11.
83. Piwoz E. Nutrition and HIV/AIDS: evidence, gaps, and priority actions. 2004. p. 1–6.
84. World Food Programme. Integration of HIV/AIDS activities with food and nutrition support in refugee settings: specific programme strategies. United Nations High Commissioner for Refugees; 2004. p. 1–97.
85. Klein DA, Emerick JE, Sylvester JE, Vogt KS. Disorders of Puberty: An approach to diagnosis and management. *Am Fam Physician.* 2017;96:590–9.
86. Majaliwa ES, Mohn A, Chiarelli F. Growth and puberty in children with HIV infection. *J Endocrinol Invest.* 2009;32:85–90.
87. Cejtin HE. Gynecologic issues in the HIV-infected woman. *Infect Dis Clin North Am.* 2008;22:709–39.

88. Bordini B, Rosenfield RL. Normal pubertal development: Part II: Clinical aspects of puberty. *Pediatr Rev.* 2011;32:281–92.
89. Haileamlak A, Hagos T, Abebe W, Abraham L, Asefa H, Teklu AM. Predictors of hospitalization among children on ART in Ethiopia: a cohort study. *Ethiop J Heal Sci.* 2017;27:53–62.
90. Dicko F, Desmonde S, Koumakpai S, Dior-Mbodj H, Kouéta F, Baeta N, *et al.* Reasons for hospitalization in HIV-infected children in West Africa. *J Int AIDS Soc.* 2014;17:1–13.
91. Krauss MR, Harris DR, Abreu T, Ferreira FG, Ruz NP, Worrel C, *et al.* Tuberculosis in HIV-infected infants, children, and adolescents in Latin America. *Braz J Infect Dis.* 2015;19:23–9.
92. Aung ZZ, Saw YM, Saw TN, Oo N, Aye HNN, Aung S, *et al.* Survival rate and mortality risk factors among TB–HIV co-infected patients at an HIV-specialist hospital in Myanmar: A 12-year retrospective follow-up study. *Int J Infect Dis.* 2019;80:10–5.
93. World Health Organization. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: recommendations for a public health approach. 2006. 1-68 p.
94. Cotton M, Innes S, Jaspan H, Madide A, Rabie H. Management of upper respiratory tract infections in children. *S Afr Fam Pr.* 2004;50:6–12.
95. Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. *J Pediatr.* 2009;154:379–84.
96. Basyal B, Jarrett H, Barnett CF. Pulmonary hypertension in HIV. *Can J Cardiol.* 2019;35:288–98.
97. Maxwell AJ, Bridges ND. Pediatric primary pulmonary hypertension. *Curr Treat Options Cardiovasc Med.* 2001;3:371–83.
98. Marwick TH. Ejection fraction pros and cons: JACC State-of-the-Art Review. *J Am Coll Cardiol.* 2018;72:2360–79.
99. Pedrotty D, Zamani P. Heart failure with preserved ejection fraction. *Clin Med (Northfield Il).* 2018;2:s24–9.

100. Fajriyah YL, Demartoto A, Murti B. The effect of depression, stigma, and peer support group, on the quality of life of people living with HIV/AIDS in Solo plus peer support group, Surakarta, Central Java. *J Heal Promot Behav*. 2018;3:27–36.
101. Cicalini S, Almodovar S, Grilli E, Flores S. Pulmonary hypertension and human immunodeficiency virus infection: Epidemiology, pathogenesis, and clinical approach. *Clin Microbiol Infect*. 2011;17:25–33.